We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


AMRI Announces Albuquerque, N.M. Manufacturing Facility Fully Operational

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "AMRI Announces Albuquerque, N.M. Manufacturing Facility Fully Operational"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

AMRI has announced that its Albuquerque, N.M. sterile injectable facility has resumed full manufacturing operations. As previously announced, in September 2014 AMRI identified an environmental deviation in one manufacturing suite as a result of a weather related business interruption. The resulting remediation has now been completed.

Commenting on its operations, William S. Marth, AMRI's President and Chief Executive Officer, said: "We are pleased to report that all suites at our OsoBio Albuquerque aseptic manufacturing facility are fully operational. I would like to acknowledge and thank our colleagues and vendors for their dedicated efforts in remediating the affected manufacturing suite as quickly as possible."

AMRI's OsoBio facility is an established provider of cGMP manufacturing and sterile filling of parenteral drugs using specialized technologies, including lyophilization.

With its cGMP aseptic filling expertise, OsoBio supports commercial scale production of liquid-filled and lyophilized parenterals.

These services are provided for both small molecule drug products as well as biologicals. Oso Biopharmaceutical Manufacturing was acquired by AMRI in July 2014.